Skip to main content
Premium Trial:

Request an Annual Quote

Scripps Translational Science Institute Awarded $34M in NIH Funding

NEW YORK (GenomeWeb) – The Scripps Translational Science Institute (STSI) announced today that it has been awarded $34 million in renewed funding from the National Institutes of Health's National Center for Advancing Translational Sciences (NCATS).

According to STSI, this newest Clinical and Translational Science Award (CTSA) is the third five-year award it has received from the NCATS since 2008, and will be used to continue the institute's efforts to combine genomic and digital technologies with bioinformatics to advance medical research and clinical care.

As part of the award, STSI will work with Rady Children's Institute for Genomic Medicine on ultra-rapid whole-genome sequencing programs in acutely ill infants, and collaborate with the California Institute for Biomedical Research (Calibr) on drug discovery for unmet medical needs. Both STSI and Calibr are affiliates of the Scripps Research Institute.

"Genomic medicine research programs at STSI and [Rady Children's] synergize significantly, especially as related to the genetics of rare and infectious diseases," Rady Children's President and CEO Stephen Kingsmore said in a statement.

"We are thrilled to enable the broader Scripps Research mission by partnering with STSI to engage the CTSA network, bringing to bear drug discovery tools that could enable rapid translation of new therapeutic approaches to patients," Calibr Chief Operating Officer Matt Tremblay added.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.